(BWAY) BrainsWay Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BWAY) BrainsWay Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This BrainsWay Ltd. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review what the deliverable looks like before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
MDD Deep TMS
Deep TMS for major depressive disorder is BrainsWay Ltd.'s biggest commercial franchise and the main Star in the BCG matrix. Depression is the portfolio's largest addressable mental-health use case, so this segment has the broadest demand pool and the strongest growth path. By end 2025, it still looks like the clearest high-share, high-growth core, driven by repeat clinic use and expanding payer access.
OCD Deep TMS
OCD Deep TMS is one of BrainsWay Ltd.'s most established cleared indications, and OCD affects about 2%-3% of adults worldwide. That gives the product a large specialty psychiatry base with repeat treatment demand. Strong clinic adoption also helps keep the brand visible in a hard-to-treat market.
Smoking Cessation
Smoking cessation is a strong growth indication for BrainsWay Ltd., because tobacco use still affects more than 1.25 billion adults worldwide and drives huge care need. It widens BrainsWay beyond depression into a larger behavioral-treatment market, where repeated use can support revenue and installed-base growth. If adoption keeps rising, it can work like a star add-on to the core Deep TMS platform.
U.S. Psychiatry Clinics
BrainsWay Ltd.’s U.S. psychiatry clinics are a Star: the U.S. is its top commercial market, and direct sales to clinics and medical centers support repeat use of Deep TMS. In 2025, this channel still drew the most strategic focus because demand kept growing and the installed base keeps generating follow-on treatments.
- Top U.S. commercial market
- Direct clinic sales drive repeat use
- Growth keeps management focus high
Deep TMS Platform
Deep TMS is BrainsWay Ltd.'s core brand and a key cash driver: its non-invasive neurostimulation platform is the company's main moat, with multiple FDA-cleared psychiatric uses and a 2024 revenue base of about $43 million. Keeping this lead matters because the platform supports pricing power, repeat treatment demand, and international scale.
- Core brand and technology asset
- Non-invasive, differentiated therapy
- Broad psychiatric positioning
- Central to future cash generation
BrainsWay’s 2025 Growth Stars: Deep TMS, OCD, Smoking Cessation
BrainsWay Ltd.’s Stars are Deep TMS for major depressive disorder, OCD, smoking cessation, and U.S. psychiatry clinics. These units combine the strongest growth with repeat treatment demand and the widest commercial reach in 2025. Deep TMS remains the core platform, with about $43 million 2024 revenue and expanding payer access.
| Star | 2025 signal |
|---|---|
| Depression | Largest market |
| OCD | 2% to 3% prevalence |
| Smoking cessation | 1.25B smokers |
| U.S. clinics | Top market |
What is included in the product
Detailed Word Document
BrainsWay’s BCG Matrix maps its neurotech products by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG Matrix for BrainsWay Ltd. to quickly spot growth bets and cash cows without the clutter
Reference Sources
Provides a clear source trail for BrainsWay Ltd. that boosts credibility and helps stakeholders verify key assumptions fast.
Cash Cows
Installed Base Support
BrainsWay’s installed base support is a cash cow because once a clinic buys a system, service, consumables, and software updates keep cash coming in with far less selling effort than a new sale. BrainsWay reported an installed base of more than 1,000 systems globally in its latest filings, so each added site can expand recurring revenue from a mature base. This is classic low-friction, follow-on revenue in an established market.
Replacement Coils
Replacement coils are a cash cow for BrainsWay Ltd. because they recur over each system’s life and sell into an installed base, not new demand. That makes revenue steadier than hardware sales, which are more lumpy. In BCG terms, this is the kind of repeat, high-visibility revenue stream that supports margin and cash flow.
Service and Maintenance
Service and maintenance are a Cash Cow for BrainsWay Ltd. because they monetize the installed fleet with low demand risk and repeatable service contracts. Growth is usually slower than new-indication sales, but the recurring base can support attractive margins and steadier cash flow. This is a high-share, low-growth support business that helps offset the volatility of capital equipment sales.
Existing MDD Centers
Existing MDD Centers are a clear Cash Cow for BrainsWay Ltd.: clinics already using Deep TMS keep buying treatment sessions, consumables, and support, so revenue is repeat-driven. Major Depressive Disorder is the company’s most established indication, with Deep TMS cleared by the U.S. FDA for MDD since 2013. That makes this base steadier and more predictable than newer pipeline programs.
- Repeat sessions drive recurring revenue
- Installed MDD base is the most mature
- Support needs stay ongoing
- Cash flow is steadier than pipeline bets
Existing OCD Centers
Existing OCD centers are a cash cow for BrainsWay Ltd. because OCD care is recurring: the DSM-5-TR estimates OCD affects about 1% to 2% of people, so trained clinics can keep serving a steady patient pool. The value here is retention and utilization, not discovery, which supports stable cash flow.
- Recurring treatment demand
- Focus on clinic retention
- Training lifts session use
- Stable cash flow, not fast growth
BrainsWay’s Recurring Revenue Engine Keeps Cash Flow Steady
BrainsWay’s cash cows are the installed base, replacement coils, service, and mature MDD/OCD clinics, because they keep generating repeat revenue after the first sale. With more than 1,000 systems installed globally, the base supports steady, lower-cost cash flow. These streams are less volatile than new hardware sales and help fund growth bets.
| Cash cow | Why it matters |
|---|---|
| Installed base | 1,000+ systems |
| Replacement coils | Recurring sales |
| Service | Repeat contracts |
| MDD/OCD centers | Ongoing treatment demand |
Preview Before You Purchase
BrainsWay Ltd. Reference Sources
The BrainsWay Ltd. BCG Matrix you’re previewing is the exact same document you’ll receive after purchase. No demo pages, no placeholders—just the fully formatted, ready-to-use file. It’s designed for clear strategic analysis and immediate professional use. Once purchased, the full version is yours to download right away.
Dogs
Bipolar Protocol
Bipolar Protocol sits in BrainsWay Ltd.’s condition set, but it has shown limited commercial traction and no material bipolar-specific revenue is disclosed in recent filings. Bipolar disorder is a specialized, harder-to-scale market, so adoption tends to stay narrow versus larger neuropsychiatric uses. That makes it a low-share, low-growth Dogs segment in the BCG Matrix.
Schizophrenia Use
Schizophrenia use is clinically important, but it is still hard to scale in TMS. Adoption is narrow, payer approval is less clear than in major depressive disorder, and if BrainsWay Ltd. keeps seeing only limited pull-through, this stays a Dog in the BCG matrix.
BrainsWay Ltd. has FDA-cleared Deep TMS for adults with schizophrenia, but commercial conversion is still the main hurdle. One line: strong clinical need does not always become strong revenue.
Autism Use
Autism use is still niche for BrainsWay Ltd.: Deep TMS is not an FDA-cleared autism indication, so adoption stays highly selective. U.S. autism prevalence is about 1 in 36 children, but reimbursement for neuromodulation in this area is still uncertain, which limits scale. So, it looks more like an optionality dog than a growth engine.
Legacy Niche Markets
BrainsWay Ltd.’s legacy niche markets fit the "Dog" bucket because they are small, fragmented, and unlikely to scale fast enough to move group revenue. They can still take sales time and service cost without delivering a matching return, so management should keep them lean or exit them.
- Low growth, limited size
- Sales effort can outweigh return
- Best kept tightly managed
Low-Volume Adjacent Uses
For BrainsWay Ltd., low-volume adjacent uses fit the Dogs bucket when clinical uptake stays weak and sales do not scale. That can still consume R&D, regulatory, and sales time, but if demand does not rise, the best-case outcome is cash neutral. The right move is to minimize or deprioritize these adjacencies and keep capital on higher-conviction uses.
- Weak adoption ties up management time.
- Low volume limits revenue scale.
- Cash flow stays flat at best.
- Cut or defer unless demand improves.
Dogs Show Clinical Promise, But Monetization Is Still Thin
BrainsWay Ltd.’s Dogs are narrow adjacencies with weak monetization: bipolar, schizophrenia, and autism use cases do not show scaled revenue, and recent filings do not break out material indication revenue. One line: clinical need is real, but cash conversion is still thin.
| Area | 2025/2026 signal |
|---|---|
| Schizophrenia | FDA-cleared, low scale |
| Bipolar | No material revenue disclosed |
| Autism | Not FDA-cleared |
Question Marks
PTSD
PTSD is a classic question mark for BrainsWay Ltd.: the U.S. alone has about 13 million adults affected in a given year, so the unmet need is large. BrainsWay’s PTSD penetration is still small versus that addressable pool, but the category can scale fast if adoption keeps rising.
Chronic Pain
Chronic pain is a huge and growing category, affecting about 20.9% of U.S. adults in 2023, or 51.6 million people. BrainsWay Ltd.'s TMS-based approach has real promise, but its commercial use in pain is still early and far below the size of the market. That makes it a Question Mark: high upside, but it needs more clinical and sales investment to prove scale.
Multiple Sclerosis
Multiple sclerosis affects about 2.8 million people worldwide, so the clinical need for new neurostimulation options is real. BrainsWay’s MS work is still early and its commercial footprint is small, so it has not yet built meaningful scale in this niche. That keeps Multiple Sclerosis in question-mark territory in the BCG Matrix.
Post-Stroke Rehab
Post-stroke rehab is a large, underpenetrated market: stroke hits about 15 million people a year worldwide, and roughly 5 million survive with lasting disability. For BrainsWay Ltd., deep TMS use in this area is still early, so any win would need strong 2025/2026 clinical evidence plus heavy sales and reimbursement work.
- Large neurological need
- Low deep TMS adoption
- High clinical proof burden
- Heavy commercial spend needed
Parkinson’s Disease
Parkinson’s disease is a question mark for BrainsWay Ltd.: the addressable market is large, with about 10 million people living with Parkinson’s globally, but the program is still early and has no meaningful commercial share yet. If clinical evidence keeps improving, it could become a real growth option, but it is not close to star status today.
- Large unmet need: ~10 million patients
- Current share: still minimal
- Stage: early commercialization
- Upside depends on stronger data
Big Markets, Big Need: BrainsWay’s Upside Is Real, but Not Yet Proven
BrainsWay Ltd.’s Question Marks are large unmet-need markets with low current penetration, so upside is real but still unproven.
PTSD, chronic pain, multiple sclerosis, post-stroke rehab, and Parkinson’s disease all need stronger 2025/2026 clinical data, reimbursement, and sales reach before they can scale.
| Area | Need |
|---|---|
| PTSD | 13M U.S. |
| Chronic pain | 51.6M U.S. |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.